This randomised, controlled clinical trial (n=128) aims to investigate whether a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with alcohol use disorder (AUD).
Status: Not yet recruiting
Start date: 2024-01-01
Phase II
Blinded
128 participants
Interventional
This double-blind, randomized, active-comparator controlled trial (n=20) will compare the effects of psilocybin-assisted psychotherapy with ketamine-assisted psychotherapy in individuals struggling with alcohol use disorder (AUD).
Status: Recruiting
Start date: 2024-02-02
Phase II
Blinded
20 participants
Interventional
This open-label, phase 2 trial (n=18) will investigate the safety and preliminary effectiveness of MDMA-assisted therapy (MDMA-AT) in military veterans with co-occurring Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD).
Status: Not yet recruiting
Start date: 2023-09-01
Phase II
Open
18 participants
Interventional
Awakn Life Sciences has announced a Phase III trial to explore the effects of ketamine-assisted therapy in the treatment of alcohol use disorder (AUD).
Status: Planned
Start date: 2023-05-01
Phase III
Blinded
280 participants
Interventional
This double-blind study (n=128) will investigate if LSD (150-250μg, 2x) will be effective in treating alcoholism (AUD). This will be compared to an 'active' placebo of 10μg LSD. The study, when conducted, will be the largest modern study of LSD for AUD.
Status: Not yet recruiting
Start date: 2023-01-01
Phase II
Blinded
128 participants
Interventional
This pilot study will collect preliminary data that measures the effects of psychedelic-assisted psychotherapy on patients struggling with alcohol use.
Status: Not yet recruiting
Start date: 2022-08-01
Phase II
Open
20 participants
Interventional
The purpose of this project is to assess the treatment efficacy of a single high dose of psilocybin administered within a protocol of psychological support to patients diagnosed with alcohol use disorder (AUD).
Status: Recruiting
Start date: 2022-10-10
Phase II
Blinded
90 participants
Interventional
96 recently detoxified alcoholics will be randomized to receive either 3 sessions ketamine (0.8 mg/kg IV over 45 minutes) or placebo plus manualised psychological therapy, or 3 sessions of ketamine or placebo plus simple psychoeducation.
Status: Completed
Start date: 2016-10-10
Phase II
Blinded
96 participants
Interventional
The purpose of this study is to determine whether psilocybin, a hallucinogenic drug, is effective in reducing depressive symptoms and amount of drinking in patients with co-occurring Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).
Status: Recruiting
Start date: 2021-04-14
Phase II
Blinded
90 participants
Interventional
The purpose of this project is to assess the feasibility and safety of administering a single dose of psilocybin to patients diagnosed with alcohol use disorder (AUD). In addition, the investigators will establish the pharmacokinetic properties of the active metabolite psilocin. This is the first step in a research project that has the overall aim to evaluate the efficacy of a single administration of psilocybin as an intervention for the treatment of AUD.
Status: Not yet recruiting
Start date: 2021-1-20
Phase II
Open
10 participants
Interventional
This open-label study (n=14) investigated the effect of MDMA-assisted psychotherapy in treating patients with alcoholism (Alcohol Use Disorder, AUD). The patients were first detoxified and subsequently underwent eight weeks of therapy, including two high doses of MDMA (125mg + 62.5mg booster) plus therapy.
Status: Completed
Start date: 2018-4-18
Phase I
Open
14 participants
Interventional
Journey Collab plan to assess the use of mescaline for treating alcohol use disorder (AUD) in the clinical trial process.
Status: Planned
Start date: 2022-03-14
Not Applicable
Open
15 participants
Interventional
Awakn Life Sciences are now planning to conduct a Phase II study exploring the safety and efficacy of MDMA-assisted psychotherapy for Alcohol Use Disorder (AUD).
Status: Planned
Start date: 2022-01-31
Phase II
Open
20 participants
Interventional
This Phase I study assessed the safety and efficacy of using MDMA-assisted psychotherapy to treat alcohol use disorder (AUD).
Status: Completed
Start date: 2020-4-20
Phase I
Open
14 participants
Interventional
The aim of the present study is to evaluate the safety, tolerability and efficacy of increasing doses of ibogaine in 12 alcoholic patients.
Status: Enrolling by invitation
Start date: 2021-10-1
Phase II
Blinded
12 participants
Interventional
This open-label trial (n=20) investigates if psilocybin (n=25mg) and Visual Healing (an 'optimised' set and setting using VR with a nature theme) will be significantly better in treating those with alcohol use disorder than a 'standard' set and setting.
Status: Active, not recruiting
Start date: 2021-3-1
Phase II
Open
20 participants
Interventional
Effects of serotonin 2A/1A receptor stimulation by psilocybin on alcohol addicted patients: a randomized double-blind placebo-controlled study.
Status: Recruiting
Start date: 2020-6-8
Phase II
Blinded
60 participants
Interventional
This project aims to evaluate the potential rapid and sustained antisuicidal and antidepressant effects of a single intranasal dose of ketamine in inpatients during a mood episode in Major Depressive Disorder (MDD) or Bipolar Disorder (BD) with or without comorbid recent abuse of alcohol.
Status: Recruiting
Start date: 2008-05-01
Phase III
Blinded
50 participants
Interventional
To evaluate if naltrexone plus ketamine is effective in reducing depression and alcohol consumption.
Status: Completed
Start date: 2016-1-5
Phase II
Open
5 participants
Interventional
The investigators will compare 3 treatment groups (ketamine plus naltrexone vs. ketamine alone vs. placebo) for treating major depressive disorder (MDD) and alcohol use disorder (AUD) in an 8-week randomized, double-blind, placebo-controlled, between-subjects trial.
Status: Recruiting
Start date: 2015-1-1
Phase I
Blinded
65 participants
Interventional
Several lines of evidence suggest that classic hallucinogens such as psilocybin can facilitate behaviour change in addictions such as alcohol dependence. The investigation is a multi-site, double-blind, active-controlled trial (n=95, 47 per group) contrasting the acute and persisting effects of psilocybin to those of diphenhydramine (placebo) in the context of outpatient alcoholism treatment.
Status: Completed
Start date: 2014-06-01
Phase II
Blinded
95 participants
Interventional
This open-label trial (n=5) investigates the effects of ketamine (35mg/70kg, 4x over 4 weeks) on those suffering from depression and alcohol dependence simultaneously.
Status: Completed
Start date: 2021-03-01
Phase I
Open
5 participants
Interventional
This trial is an open-label pilot study (N = 10) designed to assess the effects of psilocybin in alcohol dependent participants, demonstrate the feasibility of the integrated behavioral/pharmacologic intervention, and provide preliminary outcome and safety data.
Status: Completed
Start date: 2012-1-1
Phase II
Open
10 participants
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
